药物发现服务市场规模、份额和成长分析（按流程、类型、治疗领域、药物类型、技术、最终用户和地区划分）－2026-2033年产业预测

全球药物研发服务市场预计到 2024 年将达到 46.4 亿美元，到 2025 年将达到 50.1 亿美元，到 2033 年将达到 92.8 亿美元，预测期（2026-2033 年）的复合年增长率为 8%。

全球药物研发服务市场预计将迎来显着成长，这主要得益于对创新治疗方法的持续需求，以满足包括神经退化性疾病、癌症、罕见遗传疾病和心血管疾病在内的各种未被满足的医疗需求。新疾病的出现进一步凸显了对有效治疗方法的迫切需求。然而，药物研发的复杂性在于它需要毒理学、药物化学和药理学等领域专家的通力合作，因此，许多机构往往选择将这些服务外包。这种策略使製药公司和研究机构能够在利用专业知识和基础设施的同时，大幅节省成本并提高效率。倡议，研发投入的不断增加，尤其是在罕见疾病和孤儿药计画方面的投入，也带来了新的商机。然而，监管方面的挑战和专业人才的短缺可能会构成潜在的障碍。

全球药物研发服务市场驱动因素

糖尿病、失智症和心血管疾病等慢性病的高发生率对死亡率产生了显着影响，并占全球死亡人数的很大比例。慢性病发病率的上升趋势预计将推动全球药物研发服务市场的成长。随着对有效药物的需求不断增长，对创新药物研发解决方案的需求也变得日益迫切。这反过来又为药物研发公司提供了新的经济机会，使其能够应对这些健康挑战，从而推动研发进步，最终改善患者预后，并最终提升全球整体的健康福祉。

限制全球药物研发服务市场的因素

监管机构在核准过程中优先考虑药物的安全性和有效性，这对于确保市场上药品的品质至关重要。然而，这些严格的要求显着增加了药物研发和最终产品的成本。在对价格敏感的新兴经济体中，这一因素尤其突出，不断上涨的成本会阻碍新药的可及性和应用。因此，遵守监管标准的财务负担可能成为全球药物研发服务市场的一大阻碍因素，限制了那些对药品可负担性要求极高的地区的製药公司的发展机会。

全球药物研发服务市场趋势

全球药物研发服务市场正呈现显着上升趋势，这主要得益于对新型治疗方法日益增长的需求以及全球医疗保健产业的快速发展。慢性病盛行率的不断攀升促使各国政府和製药公司更加重视创新解决方案，从而加大了对临床试验的投资。随着各机构寻求提升自身研发能力并简化药物开发流程，对开发有效新治疗方法的日益重视也推动了对药物研发服务的需求。因此，随着相关人员不断适应不断变化的医疗保健格局和治疗需求，预计该市场将迎来强劲成长。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术分析

全球药物研发服务市场规模（按流程和复合年增长率划分）（2026-2033 年）

• 目标选择
• 目标检验
• 命中先导化合物
• 候选物质检验
• 其他的

全球药物研发服务市场规模（按类型和复合年增长率划分）（2026-2033 年）

• 药物化学
• 生物服务
• 药物代谢
• 医药服务
• 药物动力学

全球药物研发服务市场规模（依治疗领域划分）及复合年增长率（2026-2033 年）

• 肿瘤学
• 神经病学
• 循环系统疾病
• 呼吸系统疾病
• 糖尿病
• 其他的

全球药物研发服务市场规模（依药物类型及复合年增长率划分）（2026-2033 年）

• 低分子化合物
• 生物製剂

全球药物研发服务市场规模（依技术及复合年增长率划分）（2026-2033 年）

• 高通量筛检
• 生物晶片
• 药物基因学
• 奈米科技
• 光谱学

全球药物研发服务市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院和诊所
• 製药公司
• 生技公司
• 研究所

全球药物研发服务市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Charles River Laboratories（USA）
• WuXi AppTec（China）
• Thermo Fisher Scientific Inc.（USA）
• Evotec SE（Germany）
• Pharmaron（China）
• Labcorp（USA）
• Syngene International Limited（India）
• Eurofins Scientific（Luxembourg）
• Jubilant Biosys Limited（India）
• Curia Global, Inc.（USA）
• GenScript（USA）
• Frontage Holdings Corporation（USA）
• Piramal Enterprises Ltd.（India）
• Aragen Life Sciences Ltd.（India）
• Sygnature Discovery（UK）
• Selvita SA（Poland）
• Viva Biotech（China）
• TCG Lifesciences Pvt. Ltd.（India）
• Medicilon（China）
• Sai Life Sciences Limited（India）

结论与建议

Global Drug Discovery Services Market size was valued at USD 4.64 Billion in 2024 and is poised to grow from USD 5.01 Billion in 2025 to USD 9.28 Billion by 2033, growing at a CAGR of 8% during the forecast period (2026-2033).

The global drug discovery services market is poised for substantial growth driven by the persistent demand for innovative treatments addressing various unmet medical needs, including neurodegenerative, cancer, rare genetic, and cardiovascular diseases. The emergence of novel diseases further emphasizes the need for effective therapies. However, the intricate nature of drug discovery necessitates collaboration among experts in disciplines such as toxicology, medicinal chemistry, and pharmacology, often leading institutions to outsource these services. This strategy enables pharmaceutical companies and research organizations to leverage specialized expertise and infrastructure while achieving significant cost and time efficiencies. Moreover, increasing investments in R&D, particularly focused on rare diseases and orphan drug initiatives, highlight new revenue opportunities, even as regulatory challenges and a shortage of skilled professionals pose potential hurdles.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Drug Discovery Services market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Drug Discovery Services Market Segments Analysis

Global Drug Discovery Services Market is segmented by Process, Type, Therapeutic Area, Drug Type, Technology, End User and region. Based on Process, the market is segmented into Target Selection, Target Validation, Hit-To-Lead Identification, Candidate Validation and Others. Based on Type, the market is segmented into Medicinal Chemistry, Biology Services, Drug Metabolism, Pharmaceutical Services and Pharmacokinetics. Based on Therapeutic Area, the market is segmented into Oncology, Neurology, Cardiovascular Disease, Respiratory Disease, Diabetes and Others. Based on Drug Type, the market is segmented into Small Molecules and Biologics. Based on Technology, the market is segmented into High Throughput Screening, Biochips, Pharmacogenetics, Nanotechnology and Spectroscopy. Based on End User, the market is segmented into Hospital & Clinics, Pharmaceutical Companies, Biotechnology Companies and Research Institute. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Drug Discovery Services Market

The prevalence of chronic diseases such as diabetes, dementia, and cardiovascular conditions significantly impacts mortality rates, accounting for a substantial portion of global deaths. This rising incidence of chronic illnesses is anticipated to drive growth within the global drug discovery services market. As the demand for effective medications escalates, the need for innovative drug discovery solutions becomes increasingly vital. Consequently, companies specializing in drug discovery are presented with new economic opportunities to address these health challenges, fostering advancements in research and development aimed at improving patient outcomes and ultimately enhancing overall health and well-being worldwide.

Restraints in the Global Drug Discovery Services Market

Regulatory agencies prioritize safety and efficacy in drug approval processes, which are crucial for ensuring the quality of medicines in the market. However, these rigorous requirements substantially drive up the costs associated with drug development and the final product. This factor is particularly significant in price-sensitive emerging economies, where elevated costs can hinder the accessibility and adoption of new medications. As a result, the financial burden imposed by compliance with regulatory standards can pose a significant restraint on the Global Drug Discovery Services market, limiting opportunities for pharmaceutical companies in regions where affordability is critical.

Market Trends of the Global Drug Discovery Services Market

The Global Drug Discovery Services market is witnessing a significant upward trend driven by the increasing demand for novel therapies and the rapid advancement of the healthcare sector worldwide. The rising prevalence of chronic diseases has prompted a greater focus from governments and pharmaceutical companies on innovative solutions, leading to heightened investments in clinical trials. This growing emphasis on developing new and effective treatments is propelling the need for drug discovery services, as organizations seek to enhance their research capabilities and streamline the drug development process. Consequently, the market is poised for robust growth as stakeholders adapt to the evolving landscape of healthcare and therapeutic needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis

Global Drug Discovery Services Market Size by Process & CAGR (2026-2033)

• Market Overview
• Target Selection
• Target Validation
• Hit-To-Lead Identification
• Candidate Validation
• Others

Global Drug Discovery Services Market Size by Type & CAGR (2026-2033)

• Market Overview
• Medicinal Chemistry
• Biology Services
• Drug Metabolism
• Pharmaceutical Services
• Pharmacokinetics

Global Drug Discovery Services Market Size by Therapeutic Area & CAGR (2026-2033)

• Market Overview
• Oncology
• Neurology
• Cardiovascular Disease
• Respiratory Disease
• Diabetes
• Others

Global Drug Discovery Services Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Small Molecules
• Biologics

Global Drug Discovery Services Market Size by Technology & CAGR (2026-2033)

• Market Overview
• High Throughput Screening
• Biochips
• Pharmacogenetics
• Nanotechnology
• Spectroscopy

Global Drug Discovery Services Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospital & Clinics
• Pharmaceutical Companies
• Biotechnology Companies
• Research Institute

Global Drug Discovery Services Market Size & CAGR (2026-2033)

• North America (Process, Type, Therapeutic Area, Drug Type, Technology, End User)
  • US
  • Canada
• Europe (Process, Type, Therapeutic Area, Drug Type, Technology, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Process, Type, Therapeutic Area, Drug Type, Technology, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Process, Type, Therapeutic Area, Drug Type, Technology, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Process, Type, Therapeutic Area, Drug Type, Technology, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Charles River Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmaron (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syngene International Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Biosys Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia Global, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Frontage Holdings Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aragen Life Sciences Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sygnature Discovery (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Selvita SA (Poland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viva Biotech (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TCG Lifesciences Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medicilon (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sai Life Sciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations